T1	Premise 847 967	Pain reduction was significant from day 4 till end of treatment with SAMITAL® and from days 7 to 21 in placebo patients.
T2	Premise 776 846	No significant improvement was observed in the placebo group (n = 10).
T3	Premise 604 775	Mean scores for the severity of OM were significantly (p < 0.05 versus baseline) reduced from day 31 until the end of treatment in patients treated with SAMITAL® (n = 20).
T4	Premise 968 1127	SAMITAL® also significantly improved quality of life, as shown by improvements in scores for relevant daily activities including eating, drinking and sleeping.
T5	Premise 1229 1355	No severe adverse events were observed with SAMITAL®, and systemic absorption of relevant active ingredients was undetectable.
T6	Claim 1356 1515	SAMITAL® significantly decreased the severity of chemo/radiotherapy-induced OM in patients with head and neck cancer, with no treatment-related adverse events.
T7	Claim 1516 1705	Pain relief lasted through the treatment period, and improvements in quality of life were reflected by the significant benefits of SAMITAL® on activities like drinking, eating and speaking.
R1	Support Arg1:T5 Arg2:T6	
R2	Support Arg1:T4 Arg2:T7	
R3	Support Arg1:T1 Arg2:T7	
R4	Support Arg1:T3 Arg2:T6	
